Thornton Law Firm Reminds Meta Platforms, Inc. f/k/a Facebook Investors of Class Action Lawsuit

Not many small-cap or nano-cap companies ever manage to forge any kind of official relationship with Fortune 500-style companies. Some of the largest companies in the world asked about our technology and we knew from those discussions that our DehydraTECHTM technology is capable of delivering more important results than just making cannabis users feel their desired effects quickly. While it will take additional time to develop and approve next-generation nicotine products both in America and around the world, Lexaria is very confident that it will. Lexaria is proud to have Altria Group, Inc., owners of both flammable and non-flammable tobacco companies that have been the undisputed leaders in the US tobacco industry for decades.

In 2019, we entered into a new contractual relationship with a GMP-certified, FDA-registered manufacturing company to bring improved DehydraTECH powders to the US market with a current capacity of approximately 200,000 servings per day, all within the same facility 400,000 servings per day can be increased as needed. Lexaria is seeing strong demand from many companies requesting DehydraTECH preprocessed bulk powders for their specific product lines, and this facility allows us to meet that demand.

Lexaria’s IP strategy continues to pay off as we received our first patents in Australia in August 2019 for the use of DehydraTECH with cannabinoids to treat health conditions such as Alzheimer’s, schizophrenia, Parkinson’s and heart disease. Lexaria is using the procedural tools of the international Patent Prosecution Highway to attempt to achieve accelerated patent status in the US in 2020 on the same terms. Reinforced Health Condition-Related Claims Enables Lexaria to Better Build Relationships in the Pharmaceutical Industry; one of our goals for 2020.

As the first quarter of 2020 begins, we are seeing signs of sales growth at Lexaria that should be sustainable and support future growth. One of our existing US customers is embarking on an aggressive growth strategy from his home state to several other states next year. Another existing US customer will be launching its bottled beverage with CBD and DehydraTECH technology in the next 90 days, generating sales for Lexaria for the first time in the first quarter.

With existing customers, Lexaria expects to more than double its total sales in 2019. With an extensive pipeline of potential additional customers added in 2020, we expect further sales increases. Thanks to our good cooperation with existing corporate customers, we can say that we expect strong, sustainable sales growth in 2020 and beyond.

One of the company’s goals in 2020 is to fundamentally change our capital market strategy. Over the past six months, Lexaria has met with a number of investment banks on Wall Street as we shape our long-term capital markets strategy. Lexaria expects to have a strategy in 2020 to qualify for listing on a nationally recognized U.S. stock exchange that will allow a dramatically larger audience of investors to take into account the characteristics of Lexaria and a path to more quantity and to open up quality strategic opportunities.

The full strategic update can be found at www.lexariabioscience.com/news/

About Lexaria

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH ™ drug delivery technology changes the way active pharmaceutical ingredients get into the bloodstream, promoting healthier ingestion methods, lower total dosages, and greater lipophilic active ingredients. DehydraTECH increases bioabsorption; reduces the onset time; and masks unwanted tastes for orally administered bioactive molecules, including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple cannabis industry companies for use in cannabinoid beverages, edibles, and oral products; and to one of the world’s leading tobacco manufacturers for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and has a robust intellectual property portfolio with 16 issued and over 60 pending patents worldwide.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)

and on Facebook https://www.facebook.com/lexariabioscience/

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.
Chris Bunka, CEO
(250) 765-6424

or

NetworkNewsWire (NNW)
www.NetworkNewsWire.com

FORWARDING STATEMENTS

This press release contains forward-looking statements. Statements that are not historical facts are forward-looking statements. The company makes forward-looking public statements about its expected future financial condition, results of operations, cash flows, financing plans, business strategy, products and services, competitive position, growth opportunities, plans and goals of management for future business, including statements that contain words such as “anticipate”, “if.” “,” Believe, “” plan, “” estimate, “” expect, “” intend, “” may, “” could, “” should “,” will “and other similar expressions include forward-looking statements, including but not limited to limited to: that additional patent protection will be realized or that patent successes will deliver significant results. Such forward-looking statements are estimates that represent the company’s best judgment based on current information and involve a number of risks and uncertainties, and no assurance can be given that other factors will not affect the accuracy of such forward-looking statements. Factors that could cause actual results to differ materially from those anticipated by the company include, but are not limited to, government regulations and approvals, the management and sustaining of growth, the effects of negative publicity, litigation, competition, scientific discoveries, the Patent application and approval process and other factors that may be mentioned from time to time in the company’s public announcements and filings. There can be no assurance that the existing capital will be sufficient for the needs of the company or that it will be able to raise additional capital. There is no guarantee that the company will be able to develop, market, license, or sell edible products that contain cannabinoids, nicotine, or any other active ingredient. There is no guarantee that any proposed corporate activity, scientific research or study, business venture, letter of intent, technology license, patent application or approval, consumer study or other initiative will be conducted or, if pursued, successful. There is no guarantee that Lexaria’s postulated uses, advantages, or benefits for the patented and patent-pending technology will actually be realized in any way or in any part. None of the statements contained herein have been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure, or prevent any disease.

The CSE has not reviewed this press release and assumes no responsibility for the adequacy or accuracy of this press release.

SOURCE

Click here to contact Lexaria Bioscience Corp. (CSE: LXX, OCT: LXRP) for an investor presentation.

Comments are closed.